Protective Immunogenicity of Chemically Synthesized Peptide Fragments of Group A Streptococcal M Proteins
The M protein on the surface of group A streptococci contains epitopes that evoke type-specific protective immunity against subsequent encounters with the related serotypes of streptococci. Because some of the M proteins are closely associated with potentially harmful epitopes that give rise to antibodies cross-reactive with host tissues, especially the heart, we have undertaken studies of the covalent structures of M protein polypeptide fragments extracted with pepsin at pH 5.8 from rheumatogenic strains of group A streptococci. We have identified 35-residue peptide fragments of type 24 M protein that elicit protective, but not heart-cross-reactive antibodies. Chemically synthesized copies of a 35-residue peptide and subpeptides containing as few as 13 M protein amino acid residues were shown to be immunogenic when covalently conjugated to poly-L-lysine or tetanus toxoid. A 20-residue NH2 terminal peptide of type 5 M protein was shown to be similarly immunogenic. The immune responses in each case were protective, but not tissue cross-reactive. These results show that the whole M protein molecule is not necessary for the production of protective immunity. Moreover, selected synthetic peptide copies of the natural M protein molecule provide effective immunogens without the potential fear of tissue damage.
KeywordsLysine Polypeptide Arginine Trypsin Pseudomonas
Unable to display preview. Download preview PDF.
- 1.Stollerman GH (1975) Rheumatic fever and streptococcal infection. Grune and Stratton, New YorkGoogle Scholar
- 4.Beachey EH, Campbell GL, Ofek I (1972) Infect Immun 9: 891–896Google Scholar
- 10.Russel H, Facklam RR, Edwards LR (1975) Infect Immun 12: 679–686Google Scholar
- 21.Beachey EH, Seyer JM (1982) In: Robbins JB, Hill JC, Sadoff JC (eds) Bacterial vaccines. Thieme-Stratton, New York, pp 401–410Google Scholar
- 27.Fischetti VA, Manjula BN (1982) In: Robbins JB, Hills JC, Sadoff JC (eds) Bacterial vaccines. Thieme-Stratton, New York, pp 411–418Google Scholar